Glioma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Orbus Therapeutics, VBL Therapeutics, Candel Therapeutics, Bayer, Day One Biopharmaceuticals, DNAtrix, Laminar Pharma

PRESS RELEASE
Published January 31, 2023

The Glioma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioma pipeline products will significantly revolutionize the Glioma market dynamics.

DelveInsight’s “Glioma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Glioma, historical and forecasted epidemiology as well as the Glioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Glioma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glioma Market Insights

Glioma Overview

A glioma is a tumor of the central nervous system that arises from glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mostly occur in the brain and, rarely, in the spinal cord. Classification of gliomas is complex and based partly on the microscopic appearance of the tumor (histologic classification) and partly on the gene changes (mutations) that are implicated in tumor development. Differentiation is an important concept for the histologic classification of gliomas and refers to the “specialization” of the cell.

Some of the key facts of the Glioma Market Report:
• The Glioma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total incident population of High Grade Glioma in the 7 major markets was found to be 34,249 in 2021 and are projected to increase during the forecast period
• The total incident population of low-grade glioma (LGG) in the 7 major markets was found to be 9,078 cases in 2021 and are projected to increase during the forecast period
• The total incident population of glioma in the United States is 3,654 in 2021. The United States contributed to the largest incident population of LGG, accounting for ~ 40% of the 7MM in 2021.
• Based on GLOBOCAN estimates, 308,102 new cases of brain and central nervous system tumors were reported worldwide in 2020, with a higher prevalence in developed countries
• According to the National Organization for Rare Disorders (NORD), gliomas develop in approximately 6.6 per 100,000 individuals each year. They occur at various ages, depending on the subtype
• As per the American Brain Tumor Association, more than 79,000 new cases of brain tumors are diagnosed each year; but only about 23,880 of these are malignant (cancerous) tumors or high-grade glioma of the brain or spinal cord
• Key Glioma Companies: Orbus Therapeutics, VBL Therapeutics, Candel Therapeutics, Bayer, Day One Biopharmaceuticals, DNAtrix, Laminar Pharma, VBI Vaccines, and others
• Key Glioma Therapies: Eflornithine, Ofranergene obadenovec, CAN-2409, CAN-3110, Regorafenib, DAY101, DNX-2401, LAM561, VBI-1901, and others

Get a Free sample for the Glioma Market Report

Key benefits of the Glioma Market report:

1. Glioma market report covers a descriptive overview and comprehensive insight of the Glioma Epidemiology and Glioma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Glioma market report provides insights on the current and emerging therapies.
3. Glioma market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Glioma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Glioma market.

Download the report to understand which factors are driving Glioma epidemiology trends @ Glioma Epidemiological Insights

Glioma Market
The dynamics of the Glioma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Glioma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Glioma Epidemiology Segmentation:
The Glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
• Total Prevalence of Glioma
• Prevalent Cases of Glioma by severity
• Gender-specific Prevalence of Glioma
• Diagnosed Cases of Episodic and Chronic Glioma

Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioma market or expected to get launched during the study period. The analysis covers Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Glioma market share @ Glioma market forecast

Glioma Therapies and Key Companies
• Eflornithine: Orbus Therapeutics
• Ofranergene obadenovec: VBL Therapeutics
• CAN-2409, CAN-3110: Candel Therapeutics
• Regorafenib: Bayer
• DAY101: Day One Biopharmaceuticals
• DNX-2401: DNAtrix
• LAM561: Laminar Pharma
• VBI-1901: VBI Vaccines

Glioma Market Strengths
• Rise in Glioma market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radiotherapy techniques and novel systemic therapies
• Improvement in genomics and proteomics can lead to an acceleration in the discovery of novel treatment and drug deliverance

Scope of the Glioma Market Report
• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Glioma Companies: Orbus Therapeutics, VBL Therapeutics, Candel Therapeutics, Bayer, Day One Biopharmaceuticals, DNAtrix, Laminar Pharma, VBI Vaccines, and others
• Key Glioma Therapies: Eflornithine, Ofranergene obadenovec, CAN-2409, CAN-3110, Regorafenib, DAY101, DNX-2401, LAM561, VBI-1901, and others
• Glioma Therapeutic Assessment: Glioma current marketed and Glioma emerging therapies
• Glioma Market Dynamics: Glioma market drivers and Glioma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Glioma Unmet Needs, KOL’s views, Analyst’s views, Glioma Market Access and Reimbursement

Glioma Market Opportunities
• Increasing incidence trend will provide better therapeutic approaches for the Glioma market in the near future
• Due to lack of competitors, there is a substantial market opportunity for key players to develop anaplastic tumor targeting therapies

Table of Contents
1. Glioma Market Report Introduction
2. Executive Summary for Glioma
3. SWOT analysis of Glioma
4. Glioma Patient Share (%) Overview at a Glance
5. Glioma Market Overview at a Glance
6. Glioma Disease Background and Overview
7. Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Glioma
9. Glioma Current Treatment and Medical Practices
10. Glioma Unmet Needs
11. Glioma Emerging Therapies
12. Glioma Market Outlook
13. Country-Wise Glioma Market Analysis (2019–2032)
14. Glioma Market Access and Reimbursement of Therapies
15. Glioma Market Drivers
16. Glioma Market Barriers
17. Glioma Appendix
18. Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know more about Glioma treatment, visit @ Glioma Medications

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

WRITTEN BY

Newsmantraa